Iron chelation therapy in transfusion-dependent thalassemia patients: Current strategies and future directions

Journal of Blood Medicine

Volumn 6, Issue , 2015, Pages 197-209

  Saliba, Antoine N ^a   Harb, Afif R ^a   Taher, Ali T ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Iron chelation therapy; Iron overload; Thalassemia; Transfusion; Transfusion dependent thalassemia

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON; IRON CHELATING AGENT;

ARTHRALGIA; CHELATION THERAPY; CREATININE BLOOD LEVEL; DRUG EFFICACY; ENDOCRINE GLAND; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART; HUMAN; HYPERTRANSAMINASEMIA; INJECTION SITE REACTION; IRON CHELATION; IRON OVERLOAD; KIDNEY FAILURE; LIVER; LIVER FAILURE; META ANALYSIS (TOPIC); MONOTHERAPY; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REFRACTORY ANEMIA; REVIEW; THALASSEMIA; TRANSFUSION; UNSPECIFIED SIDE EFFECT; YERSINIA INFECTION;

EID: 84939121382     PISSN: None     EISSN: 11792736     Source Type: Journal    
DOI: 10.2147/JBM.S72463     Document Type: Review

References (107)

1. Pietrangelo A. Physiology of iron transport and the hemochromatosis gene. Am J Physiol Gastrointest Liver Physiol. 2002; 282(3): G403-G414.
2. Knutson M, Wessling-Resnick M. Iron metabolism in the reticuloendothelial system. Crit Rev Biochem Mol Biol. 2003; 38(1): 61-88.
3. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012; 120(18): 3657-3669.
4. Fillet G, Beguin Y, Baldelli L. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood. 1989; 74(2): 844-851.
5. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci. 2000; 23(3): 185-192.
6. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306(5704): 2090-2093.
7. Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol. 2008; 15(3): 169-175.
8. Tanno T, Porayette P, Sripichai O, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood. 2009; 114(1): 181-186.
9. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007; 13(9): 1096-1101.
10. Tanno T, Rabel A, Lee YT, Yau YY, Leitman SF, Miller JL. Expression of growth differentiation factor 15 is not elevated in individuals with iron deficiency secondary to volunteer blood donation. Transfusion. 2010; 50(7): 1532-1535.
11. Casanovas G, Vujić Spasic M, Casu C, et al. The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica. 2013; 98(3): 444-447.
12. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014; 46(7): 678-684.
13. Novartis. Desferal (Deferoxamine Mesylate) Prescribing Information. Switzerland: Novartis Pharmaceuticals; 2011.
14. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood. 1996; 88(2): 705-713.
15. Barry M, Flynn DM, Letsky EA, Risdon RA. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress. Br Med J. 1974; 2(5909): 16-20.
16. Modell B, Letsky EA, Flynn DM, Peto R, Weatherall DJ. Survival and desferrioxamine in thalassaemia major. Br Med J. 1982; 284(6322): 1081-1084.
17. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004; 89(10): 1187-1193.
18. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994; 331(9): 567-573.
19. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004; 127(3): 348-355.
20. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000; 95(4): 1229-1236.
21. Cohen A, Martin M, Mizanin J, Konkle DF, Schwartz E. Vision and hearing during deferoxamine therapy. J Pediatr. 1990; 117(2 pt 1): 326-330.
22. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986; 314(14): 869-873.
23. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Hematology Am Soc Hematol Educ Program. 2004; 1: 14-34.
24. Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007; 47(10): 1919-1929.
25. Agency EM. Ferriprox: EPAR-Product Information; 2009. Available from: http://www. ema. europa. eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000236/WC500022050. pdf, 2014.
26. Traynor K. Deferiprone approved for iron overload. Am J Health Syst Pharm. 2011; 68(22): 2106.
27. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood. 2006; 107(9): 3733-3737.
28. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003; 88(5): 489-496.
29. Addis A, Loebstein R, Koren G, Einarson TR. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). Eur J Clin Pharmacol. 1999; 55(1): 1-6.
30. Maggio A, D'Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002; 28(2): 196-208.
31. Taher A, Sheikh-Taha M, Sharara A, et al. Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study. Acta Haematol. 2005; 114(3): 146-149.
32. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002; 360(9332): 516-520.
33. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006; 107(9): 3738-3744.
34. Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiov Magn Reson. 2009; 11: 20.
35. Pennell DJ, Carpenter JP, Roughton M, Cabantchik Z. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J Cardiov Magn Reson. 2011; 13: 45.
36. Maggio A, Vitrano A, Capra M, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis. 2009; 42(3): 247-251.
37. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003; 102(5): 1583-1587.
38. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998; 339(7): 417-423.
39. Wu SF, Peng CT, Wu KH, Tsai CH. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. Hemoglobin. 2006; 30(2): 215-218.
40. Wanless IR, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood. 2002; 100(5): 1566-1569.
41. Taher A, Aoun E, Sharara AI, et al. Five-year trial of deferiprone chelation therapy in thalassaemia major patients. Acta Haematol. 2004; 112(4): 179-183.
42. Exjade (deferasirox) [prescribing information]. Switzerland: Novartis Pharmaceuticals; 2005.
43. Goldberg SL, Giardina PJ, Chirnomas D, Esposito J, Paley C, Vichinsky E. The palatability and tolerability of deferasirox taken with different beverages or foods. Pediatr Blood Cancer. 2013; 60(9): 1507-1512.
44. Séchaud R, Dutreix C, Balez S, et al. Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. Int J Clin Pharmacol Ther. 2008; 46(2): 102-108.
45. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006; 91(7): 873-880.
46. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica. 2006; 91(10): 1343-1351.
47. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006; 107(9): 3455-3462.
48. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008; 80(2): 168-176.
49. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009; 82(6): 458-465.
50. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of. 30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009; 147(5): 752-759.
51. Deugnier Y, Turlin B, Ropert M, et al. Improvement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 years. Gastroenterology. 2011; 141(4): 1202-1211, 1211. e1201-1203.
52. Cappellini MD, Porter J, El-Beshlawy A, EPIC Study Investigators, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010; 95(4): 557-566.
53. Porter JB, Elalfy MS, Taher AT, et al. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Ann Hematol. 2013; 92(2): 211-219.
54. Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major. Haematologica. 2012; 97(6): 842-848.
55. Pennell DJ, Porter JB, Piga A, CORDELIA study investigators, et al. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA). Blood. 2014; 123(10): 1447-1454.
56. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998; 103(2): 361-364.
57. Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood. 2001; 97(3): 792-798.
58. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med. 2001; 138(2): 130-138.
59. Evans P, Kayyali R, Hider RC, Eccleston J, Porter JB. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Trans Res. 2010; 156(2): 55-67.
60. Pennell DJ, Udelson JE, Arai AE, American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging, et al. Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American Heart Association. Circulation. 2013; 128(3): 281-308.
61. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003; 121(1): 187-189.
62. Gomber S, Saxena R, Madan N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian Pediatr. 2004; 41(1): 21-27.
63. Ha SY, Chik KW, Ling SC, et al. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin. 2006; 30(2): 263-274.
64. Aydinok Y, Ulger Z, Nart D, et al. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica. 2007; 92(12): 1599-1606.
65. El-Beshlawy A, Manz C, Naja M, et al. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Ann Hematol. 2008; 87(7): 545-550.
66. Lai ME, Grady RW, Vacquer S, et al. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to deferoxamine alone. Blood Cells Mol Dis. 2010; 45(2): 136-139.
67. Ladis V, Chouliaras G, Berdoukas V, et al. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. Eur J Haematol. 2010; 85(4): 335-344.
68. Telfer PT, Warburton F, Christou S, et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica. 2009; 94(12): 1777-1778.
69. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007; 115(14): 1876-1884.
70. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiov Magn Reson. 2008; 10: 12.
71. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010; 148(3): 466-475.
72. Kwiatkowski JL. Real-world use of iron chelators. Hematology Am Soc Hematol Educ Program. 2011; 2011: 451-458.
73. Galanello R, Kattamis A, Piga A, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica. 2006; 91(9): 1241-1243.
74. Abdelrazik N. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience. Hematology. 2007; 12(6): 577-585.
75. Maggio A, Vitrano A, Capra M, et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol. 2009; 145(2): 245-254.
76. Maggio A, Filosa A, Vitrano A, et al. Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis. 2011; 47(3): 166-175.
77. Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. The Cochrane Database of Syst Rev. 2013; 8: Cd004450.
78. Otto-Duessel M, Brewer C, Gonzalez I, Nick H, Wood JC. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. Acta Haematol. 2008; 120(2): 123-128.
79. Voskaridou E, Komninaka V, Karavas A, Terpos E, Akianidis V, Christoulas D. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with beta-thalassemia major and severe iron burden. Transfusion. 2014; 54(3): 646-649.
80. Lal A, Sweeters N, Herz M, et al. Safety of combined chelation therapy with deferasirox and deferoxamine in transfusion-dependent thalassemia [Abstract]. Blood. 2009; 114: 2021.
81. Grady RW, Galanello R, Randolph RE, Kleinert DA, Dessi C, Giardina PJ. Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine. Haematologica. 2013; 98(1): 129-135.
82. Lal A, Porter J, Sweeters N, et al. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis. 2013; 50(2): 99-104.
83. Cassinerio E, Orofino N, Roghi A, et al. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients. Blood Cells Mol Dis. 2014; 53(3): 164-167.
84. Aydinok Y, Kattamis A, Cappellini MD, et al. Deferasirox-deferoxamine combination therapy reduces cardiac iron with rapid liver iron Removal in patients with severe transfusional iron overload (HYPERION). In: 55th ASH annual meeting; December 8, 2013; New Orleans, LA.
85. Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia; 2015. Available from: https://clinicaltrials. gov/ct2/show/NCT01709032?term=Deferiprone+AND+deferasirox&rank=1, 2015.
86. Study of Efficacy, Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload. 2015. Available from: https://clinicaltrials. gov/ct2/show/NCT01511848?term=Deferiprone+AND+deferasirox&rank=3. Accessed 2015.
87. Clinical Trial of Deferasirox Combination Treatment with Deferiprone in Thalassaemia Patients; 2015. Available from: https://clinicaltrials. gov/ct2/show/NCT02198508?term=Deferiprone+AND+deferasirox&rank=4, 2015.
88. Voskaridou E, Christoulas D, Terpos E. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. Br J Haematol. 2011; 154(5): 654-656.
89. Balocco M, Carrara P, Pinto V, Forni GL. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients. Am J Hematol. 2010; 85(6): 460-461.
90. Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. 2008; 93(5): 741-752.
91. Yardumian A, Telfer P, Darbyshire P. Standards for the Clinical Care of Children and Adults with Thalassaemia in the UK. 2nd ed; 2008. Available from: http://www. hbpinfo. com/ukts-standards-2008. pdf, 2015.
92. Vichinsky E, Levine L. Standard-of-Care Clinical Practice Guidelines; 2012. Available from: http://thalassemia. com/treatment-guidelines-5. aspx#gsc. tab=0, 2015.
93. Sayani F, Warner M, Wu J, Wong-Rieger D, Humphreys K, Odame I. Guidelines for the Clinical Care of Patients with Thalassemia in Canada. Nicosia, Cyprus: Thalassaemia International Federation; 2009.
94. Ho PJ, Tay L, Lindeman R, Catley L, Bowden DK. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. Intern Med J. 2011; 41(7): 516-524.
95. Musallam KM, Angastiniotis M, Eleftheriou A, Porter JB. Cross-talk between available guidelines for the management of patients with beta-thalassemia major. Acta Haematol. 2013; 130(2): 64-73.
96. Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. Guidelines for the Management of Transfusion Dependent Thalassemia. 3rd ed. Nicosia, Cyprus: Thalassaemia International Federation; 2014.
97. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000; 355(9220): 2051-2052.
98. Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet); 2015. Available from: https://clinicaltrials. gov/ct2/show/study/NCT02125877?term=Deferasirox&rank=30, 2015.
99. Pilot Study of the Pharmacokinetic Profile of a Single Dose of Deferiprone Sustained-Release Formulation in Healthy Volunteers; 2015. Available from: https://clinicaltrials. gov/ct2/show/NCT02189941?term=deferiprone&rank=5. Accessed 2015.
100. Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease; 2015. Available from: https://clinicaltrials. gov/ct2/show/study/NCT01835496?term=deferiprone&rank=9. Accessed Jan 2015.
101. Bergeron RJ, Wiegand J, McManis JS, Bharti N, Singh S. Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues. J Med Chem. 2008; 51(13): 3913-3923.
102. Bergeron RJ, Wiegand J, Bharti N, McManis JS, Singh S. Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity. Biometals. 2011; 24(2): 239-258.
103. Bergeron RJ, Bharti N, Wiegand J, McManis JS, Singh S, Abboud KA. The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues. J Med Chem. 2010; 53(7): 2843-2853.
104. Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients with β-Thalassemia; 2015. Available from: https://clinicaltrials. gov/ct2/show/record/NCT02274233?term=sp+420&rank=1.
105. Rienhoff HY Jr, Viprakasit V, Tay L, et al. A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica. 2011; 96(4): 521-525.
106. Suragani RN, Cawley SM, Li R, et al. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine beta-thalassemia. Blood. 2014; 123(25): 3864-3872.
107. Dussiot M, Maciel TT, Fricot A, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in beta-thalassemia. Nat Med. 2014; 20(4): 398-407.